ChiCTR2400085577 版本V1.0 版本创建时间2024/06/12 17:27:23 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400085577 

最近更新日期:

Date of Last Refreshed on:

2024-06-12 17:27:19 

注册时间:

Date of Registration:

2024-06-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于循证医学的补肾除湿法联合软骨修复技术治疗早期膝骨关节炎的临床研究

Public title:

Clinical study of invigorating kidney and dehumidification based on evidence-based medicine combined with cartilage repair technology in the treatment of early knee osteoarthritis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于循证医学的补肾除湿法联合软骨修复技术治疗早期膝骨关节炎的临床研究

Scientific title:

Clinical study of invigorating kidney and dehumidification based on evidence-based medicine combined with cartilage repair technology in the treatment of early knee osteoarthritis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

陈博弈 

研究负责人:

荆琳 

Applicant:

Boyi Chen 

Study leader:

Lin Jing 

申请注册联系人电话:

Applicant telephone:

+86 172 0032 4680

研究负责人电话:

Study leader's
telephone:

+86 137 1882 2649

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1767814835@qq.com

研究负责人电子邮件:

Study leader's E-mail:

13718822649@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区花家地街中国中医科学院望京医院

研究负责人通讯地址:

北京市朝阳区花家地街中国中医科学院望京医院

Applicant address:

Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing

Study leader's address:

Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国中医科学院望京医院

Applicant's institution:

Wangjing Hospital, China Academy of Chinese Medical Sciences

研究负责人所在单位:

中国中医科学院望京医院

Affiliation of the Leader:

Wangjing Hospital, China Academy of Chinese Medical Sciences

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

WIEC-KT-2024-017-P002

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国中医科学院望京医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Wangjing Hospital, China Academy of Chinese Medical Sciences

伦理委员会批准日期:

Date of approved by ethic committee:

2024-04-24 00:00:00

伦理委员会联系人:

李浩

Contact Name of the ethic committee:

Hao Li

伦理委员会联系地址:

北京市朝阳区花家地街中国中医科学院望京医院

Contact Address of the ethic committee:

Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 8473 9681

伦理委员会联系人邮箱:

Contact email of the ethic committee:

wjyyec@126.com

研究实施负责(组长)单位:

中国中医科学院望京医院

Primary sponsor:

Wangjing Hospital, China Academy of Chinese Medical Sciences

研究实施负责(组长)单位地址:

北京市朝阳区花家地街中国中医科学院望京医院

Primary sponsor's address:

Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

朝阳区

Country:

China

Province:

Beijing

City:

Chaoyang District

单位(医院):

中国中医科学院望京医院

具体地址:

北京市朝阳区花家地街中国中医科学院望京医院

Institution
hospital:

Wangjing Hospital, China Academy of Chinese Medical Sciences

Address:

Wangjing Hospital, China Academy of Chinese Medical Sciences, Huajiadi Street, Chaoyang District, Beijing

经费或物资来源:

中国中医科学院望京医院高水平中医医院建设项目中医药临床循证研究专项

Source(s) of funding:

TCM clinical evidence-based Research program of high-level TCM hospital Construction project, Wangjing Hospital, China Academy of Chinese Medical Sciences

研究疾病:

膝骨关节炎  

Target disease:

Knee osteoarthritis

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

(1)基于循证医学理论,明确补肾除湿法联合软骨修复技术在治疗早期KOA中的有效性、安全性及作用机理; (2)从临床层面为 KOA 的治疗提供新思路和新方法,从而形成中西医结合治疗 KOA的技术规范,提高 KOA 的临床疗效。  

Objectives of Study:

(1) Based on the theory of evidence-based medicine, to clarify the effectiveness, safety and mechanism of invigorating kidney and dehumidification combined with cartilage repair technology in the treatment of early KOA; (2) To provide new ideas and new methods for the treatment of KOA from the clinical level, so as to form a technical specification for the treatment of KOA with integrated Chinese and Western medicine, and improve the clinical efficacy of KOA.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

纳入标准: ①符合西医和中医诊断标准;(西医诊断标准:1.根据美国风湿病学会(ACR)膝骨性关节炎的诊断标准: ①.1 个月里大多数日子膝痛;②.关节活动时有响声;③.晨僵<30 分钟;④.年龄>38 岁;⑤.膝关节骨性肿胀伴弹响;⑥.膝关节骨性肿胀不伴弹响;最少存在 ①~④ 或 ①,②,③,⑤或 ① 和 ⑥ 即可诊断。 2.Kellgren-LawranceX 线分级(分 5 级):0 级:正常;I 级:可疑关节间隙狭窄和可能唇样增生; II 级:肯定骨赘和可能关节间隙狭窄;III 级:中度多发骨赘,肯定关节间隙狭窄、硬化和可能骨端变形; IV 级:大骨赘,明显关节间隙狭窄,严重硬化和肯定骨端变形。 3.关节软骨退行性变 MRI 分级(RECHT 分级) 0 级:正常关节软骨;I 级:软骨分层结构消失,软骨内出现局灶性低信号区,软骨表面光滑; II 级:软骨表面轮廓轻至中度不规则,软骨缺损深度未及全层厚度的 50%; III 级:软骨表面轮廓中至重度不规则,软骨缺损深度深达全层厚度的 50%以上但未见完全脱落。 IV 级:软骨全层缺损、剥脱,软骨下骨质暴露,伴或不伴软骨下骨质信号改变。 中医诊断标准:中医诊断及证候标准参考 2018 版中国中西医结合学会骨伤科专业委员会《膝骨关节炎中西医结合诊疗指南》中肝肾亏虚型 KOA 诊断标准:关节隐隐作痛,腰膝酸软无力,遇劳更甚,舌质红,少苔,脉沉细弱。满足上述者方可进行诊断。) ②符合所研究诊疗技术适应症的要求; ③年龄>38 岁; ④符合 Kellgren-Lawrance X 线分级 0 级、I 级、II 级; ⑤MRI 显示局灶性 RECHT 分级 III、IV 级软骨退变。 ⑥签署知情同意书。

Inclusion criteria

Inclusion criteria: ① Meet the diagnostic standards of Western medicine and Chinese medicine; (Western diagnostic criteria: 1. According to the American College of Rheumatology (ACR) diagnostic criteria for knee osteoarthritis: ①. Knee pain most days of the month; 2. There is a sound when the joint is moving; 3. Morning stiffness <30 minutes; ④. Age >38 years old; ⑤. Bone swelling of knee joint with bouncing; 6. bone swelling of knee joint without rattle; At least ① ~ ④ or ①, ②, ③, ⑤ or ① and ⑥ can be diagnosed. 2.Kellgren-LawranceX line classification (divided into 5 levels) : Level 0: normal; Grade I: Suspected joint space stenosis and possible labial hyperplasia; Grade II: Definite osteophytes and possible joint space stenosis; Grade III: moderately multiple osteophytes, certain joint space stenosis, sclerosis, and possible bone end deformation; Grade IV: Large osteophytes, marked joint space narrowing, severe sclerosis, and definite end deformation. 3. MRI grading of articular cartilage degeneration (RECHT grading) Grade 0: Normal articular cartilage; Grade I: The hierarchical structure of cartilage disappeared, the focal low signal area appeared in the cartilage, and the cartilage surface was smooth; Grade II: The surface profile of the cartilage is light to moderate irregular, and the depth of the cartilage defect is less than 50% of the full thickness. Grade III: Moderate to severe irregularities in the surface profile of the cartilage, with a depth of cartilage defect of more than 50% of the full thickness but no complete detachment. Grade IV: full-layer cartilage defect, exfoliation, subchondral bone exposure, with or without subchondral bone signal changes. TCM diagnostic criteria: TCM diagnostic and syndrome criteria refer to the 2018 edition of the Chinese Association of Integrated Traditional and Western Medicine Orthopedics Professional Committee "Knee Osteoarthritis of Traditional Chinese and Western Medicine Integrated Diagnosis and Treatment Guide" in the diagnosis and treatment of liver and kidney deficiency type KOA diagnostic criteria: dull joint pain, waist and knee weakness, more severe in case of labor, red tongue, less mossiness, pulse heavy and weak. Only those who meet the above criteria can be diagnosed.) (2) meet the requirements of the clinical indications studied; ③ Age >38 years old; ④ In line with Kellgren-Lawrance X-ray classification level 0, I, II; (5) MRI showed focal RECHT grade III and IV cartilage degeneration. ⑥ Sign the informed consent.

排除标准:

排除标准: ①不符合上述诊断标准和纳入标准者。 ②已接受其它有关治疗,可能影响本研究的效应指标观测者。 ③合并心脑血管、肝肾等危及生命的原发性疾病以及精神病患者。 ④排除研究疾病: a.风湿类疾病:类风湿性关节炎、强直性脊柱炎等; b.感染性关节炎:关节结核、化脓性关节炎等; c.反应性关节炎:过敏性关节炎、血小板减少性紫癜性关节炎等; d.代谢性关节病:大骨节病、痛风等; e.关节内肿瘤; f.其它特异性关节病。

Exclusion criteria:

Exclusion criteria: ① Those who do not meet the above diagnostic criteria and inclusion criteria. ② Observers who have received other relevant treatments that may affect the effect indicators of this study. ③ Patients with life-threatening primary diseases such as cardiovascular and cerebrovascular diseases, liver and kidney diseases and mental disorders. ④ Excluded diseases for study: a. Rheumatic diseases: rheumatoid arthritis, ankylosing spondylitis, etc.; b. Infectious arthritis: joint tuberculosis, suppurative arthritis, etc.; c. Reactive arthritis: allergic arthritis, thrombocytopenic arthritis, etc.; d. Metabolic arthropathy: Kaschin-beck disease, gout, etc.; e. Intraarticular tumors; f. Other specific joint diseases.

研究实施时间:

Study execute time:

From 2023-11-25 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-06-12 00:00:00 To 2025-12-31 00:00:00

干预措施:

Interventions:

组别:

试验 1 组

样本量:

30

Group:

Test group 1

Sample size:

干预措施:

行软骨修复技术

干预措施代码:

Intervention:

Cartilage repair techniques were performed

Intervention code:

组别:

试验 2 组

样本量:

30

Group:

Test group 2

Sample size:

干预措施:

口服补肾除湿方药联合软骨修复技术

干预措施代码:

Intervention:

Oral tonifying kidney dehumidifying prescription combined with cartilage repair technique

Intervention code:

组别:

对照组

样本量:

30

Group:

Control group

Sample size:

干预措施:

口服西药(双氯芬酸钠缓释片+硫酸氨基葡萄糖胶囊)

干预措施代码:

Intervention:

Oral Western medicine (diclofenac sodium sustained-release tablets + glucosamine sulfate capsules)

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京  

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院望京医院  

单位级别:

三甲  

Institution
hospital:

Wangjing Hospital of China Academy of Chinese Medicine Sciences

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

血清指标

指标类型:

主要指标

Outcome:

Serum index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Roberts MRI 评价标准

指标类型:

次要指标

Outcome:

Roberts MRI evaluation criteria

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

MOCART MRI 软骨修复评分

指标类型:

次要指标

Outcome:

MOCART MRI cartilage repair score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

WOMAC 骨关节炎指数评分

指标类型:

主要指标

Outcome:

WOMAC Osteoarthritis Index score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

Lequesne 指数评分

指标类型:

主要指标

Outcome:

Lequesne Index score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中医临床症状评分

指标类型:

次要指标

Outcome:

TCM clinical symptom score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 38 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

依托中国中医科学院临床基础医学研究所评价中心给予随机号

Randomization Procedure (please state who generates the random number sequence and by what method):

The random number was based on the Evaluation Center of the Institute of Clinical Basic Medicine, China Academy of Chinese Medical Sciences.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

仅对数据统计人员设盲。

Blinding:

Blinding was to the data statisticians only.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

本研究分析的数据集可根据合理要求从通讯作者处获取。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The datasets analyzed during the current study are available from the corresponding author upon reasonable request.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集和管理由两部分组成,一为病例记录表,二为特定人员进行电子信息采集和管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection and management consisted of two parts, one was Case Record Form (CRF), and the other was electronic information collection and management for specific personnel.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-06-12 17:27:19